Product Details for NDA 207946
INVEGA HAFYERA (PALIPERIDONE PALMITATE)
1.092GM/3.5ML (312MG/ML)
Marketing Status: Prescription
1.560GM/5ML (312MG/ML)
Marketing Status: Prescription
273MG/0.875ML (273MG/0.875ML)
Marketing Status: Prescription
410MG/1.315ML (311.79MG/ML)
Marketing Status: Prescription
546MG/1.75ML (312MG/ML)
Marketing Status: Prescription
819MG/2.625ML (312MG/ML)
Marketing Status: Prescription
1.092GM/3.5ML (312MG/ML)
Marketing Status: Prescription
Active Ingredient: PALIPERIDONE PALMITATE
Proprietary Name: INVEGA HAFYERA
Dosage Form; Route of Administration: SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
Strength: 1.092GM/3.5ML (312MG/ML)
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N207946
Product Number: 005
Approval Date: Aug 30, 2021
Applicant Holder Full Name: JANSSEN PHARMACEUTICALS INC
Marketing Status: Prescription
Patent and Exclusivity Information
INVEGA HAFYERA (PALIPERIDONE PALMITATE)
Proprietary Name: INVEGA HAFYERA
Dosage Form; Route of Administration: SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
Strength: 1.092GM/3.5ML (312MG/ML)
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N207946
Product Number: 005
Approval Date: Aug 30, 2021
Applicant Holder Full Name: JANSSEN PHARMACEUTICALS INC
Marketing Status: Prescription
Patent and Exclusivity Information
1.560GM/5ML (312MG/ML)
Marketing Status: Prescription
Active Ingredient: PALIPERIDONE PALMITATE
Proprietary Name: INVEGA HAFYERA
Dosage Form; Route of Administration: SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
Strength: 1.560GM/5ML (312MG/ML)
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N207946
Product Number: 006
Approval Date: Aug 30, 2021
Applicant Holder Full Name: JANSSEN PHARMACEUTICALS INC
Marketing Status: Prescription
Patent and Exclusivity Information
INVEGA TRINZA (PALIPERIDONE PALMITATE)
Proprietary Name: INVEGA HAFYERA
Dosage Form; Route of Administration: SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
Strength: 1.560GM/5ML (312MG/ML)
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N207946
Product Number: 006
Approval Date: Aug 30, 2021
Applicant Holder Full Name: JANSSEN PHARMACEUTICALS INC
Marketing Status: Prescription
Patent and Exclusivity Information
273MG/0.875ML (273MG/0.875ML)
Marketing Status: Prescription
Active Ingredient: PALIPERIDONE PALMITATE
Proprietary Name: INVEGA TRINZA
Dosage Form; Route of Administration: SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
Strength: 273MG/0.875ML (273MG/0.875ML)
Reference Listed Drug: Yes
Reference Standard: Yes
TE Code:
Application Number: N207946
Product Number: 001
Approval Date: May 18, 2015
Applicant Holder Full Name: JANSSEN PHARMACEUTICALS INC
Marketing Status: Prescription
Patent and Exclusivity Information
INVEGA TRINZA (PALIPERIDONE PALMITATE)
Proprietary Name: INVEGA TRINZA
Dosage Form; Route of Administration: SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
Strength: 273MG/0.875ML (273MG/0.875ML)
Reference Listed Drug: Yes
Reference Standard: Yes
TE Code:
Application Number: N207946
Product Number: 001
Approval Date: May 18, 2015
Applicant Holder Full Name: JANSSEN PHARMACEUTICALS INC
Marketing Status: Prescription
Patent and Exclusivity Information
410MG/1.315ML (311.79MG/ML)
Marketing Status: Prescription
Active Ingredient: PALIPERIDONE PALMITATE
Proprietary Name: INVEGA TRINZA
Dosage Form; Route of Administration: SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
Strength: 410MG/1.315ML (311.79MG/ML)
Reference Listed Drug: Yes
Reference Standard: Yes
TE Code:
Application Number: N207946
Product Number: 002
Approval Date: May 18, 2015
Applicant Holder Full Name: JANSSEN PHARMACEUTICALS INC
Marketing Status: Prescription
Patent and Exclusivity Information
INVEGA TRINZA (PALIPERIDONE PALMITATE)
Proprietary Name: INVEGA TRINZA
Dosage Form; Route of Administration: SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
Strength: 410MG/1.315ML (311.79MG/ML)
Reference Listed Drug: Yes
Reference Standard: Yes
TE Code:
Application Number: N207946
Product Number: 002
Approval Date: May 18, 2015
Applicant Holder Full Name: JANSSEN PHARMACEUTICALS INC
Marketing Status: Prescription
Patent and Exclusivity Information
546MG/1.75ML (312MG/ML)
Marketing Status: Prescription
Active Ingredient: PALIPERIDONE PALMITATE
Proprietary Name: INVEGA TRINZA
Dosage Form; Route of Administration: SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
Strength: 546MG/1.75ML (312MG/ML)
Reference Listed Drug: Yes
Reference Standard: Yes
TE Code:
Application Number: N207946
Product Number: 003
Approval Date: May 18, 2015
Applicant Holder Full Name: JANSSEN PHARMACEUTICALS INC
Marketing Status: Prescription
Patent and Exclusivity Information
INVEGA TRINZA (PALIPERIDONE PALMITATE)
Proprietary Name: INVEGA TRINZA
Dosage Form; Route of Administration: SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
Strength: 546MG/1.75ML (312MG/ML)
Reference Listed Drug: Yes
Reference Standard: Yes
TE Code:
Application Number: N207946
Product Number: 003
Approval Date: May 18, 2015
Applicant Holder Full Name: JANSSEN PHARMACEUTICALS INC
Marketing Status: Prescription
Patent and Exclusivity Information
819MG/2.625ML (312MG/ML)
Marketing Status: Prescription
Active Ingredient: PALIPERIDONE PALMITATE
Proprietary Name: INVEGA TRINZA
Dosage Form; Route of Administration: SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
Strength: 819MG/2.625ML (312MG/ML)
Reference Listed Drug: Yes
Reference Standard: Yes
TE Code:
Application Number: N207946
Product Number: 004
Approval Date: May 18, 2015
Applicant Holder Full Name: JANSSEN PHARMACEUTICALS INC
Marketing Status: Prescription
Patent and Exclusivity Information
Proprietary Name: INVEGA TRINZA
Dosage Form; Route of Administration: SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
Strength: 819MG/2.625ML (312MG/ML)
Reference Listed Drug: Yes
Reference Standard: Yes
TE Code:
Application Number: N207946
Product Number: 004
Approval Date: May 18, 2015
Applicant Holder Full Name: JANSSEN PHARMACEUTICALS INC
Marketing Status: Prescription
Patent and Exclusivity Information